Rosenblatt analyst initiates coverage on Magnite Inc. with a Buy rating and $18 price forecast. Potential growth if regulatory actions level the field with Google.
Hotel and casino entertainment company Caesars Entertainment (NASDAQ:CZR) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 1.9% year on year to $2.79 billion. Its GAAP loss of $0.54 per share was significantly below analysts’ consensus estimates.
Communications chips maker Qorvo (NASDAQ: QRVO) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 7.6% year on year to $869.5 million. Guidance for next quarter’s revenue was optimistic at $775 million at the midpoint, 2.4% above analysts’ estimates. Its non-GAAP profit of $1.42 per share was 41.6% above analysts’ consensus estimates.
Machinery provider H&E (NASDAQ:HEES) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 14% year on year to $319.5 million. Its non-GAAP profit of $0.03 per share was 95.5% below analysts’ consensus estimates.
Looking for the most active S&P500 stocks in today's session? Join us as we dive into the US markets on Tuesday and discover the stocks that are dominating the trading activity and setting the pace for the market.
Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 132% in the afternoon session after the company announced plans to make it easier for its members to access Eli Lilly's FDA-approved weight loss drug Zepbound. Given the success of weight loss drugs with regulatory approval and the crackdown on knock-offs, expanding the distribution of Zepbound should accelerate adoption. Additionally, companies such as WeightWatchers should benefit from increased sales volume and greater customer loyalty as they align themselves with medically endorsed treatments.
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO)
fell 34.8% in the afternoon session after the company reported disappointing first-quarter 2025 earnings as sales fell below Wall Street's expectations. Another blemish was that while full-year revenue guidance was raised, full-year EBITDA guidance was maintained, signaling that profit margins for the year would be lower than initially expected. On the other hand, NeoGenomics beat analysts' EPS expectations, and its full-year revenue guidance exceeded Wall Street's estimates. Overall, this quarter was mixed. The areas below expectations seemed to be driving the move.
Wall Street divided on dollar's future. Wells Fargo bullish, Goldman Sachs bearish. Dollar hit high short positions, oversold, due to US policy uncertainty.
Faraday Future has seen its stock climb 50% over the past week. The California-based electric vehicle maker recently appointed founder YT Jia as Co-CEO.
